Imed19 Betriebs GmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Imed19 Betriebs GmbH in Vienna, research in cardiovascular diseases focuses on conditions such as heart failure, hypertension, and broader cardiovascular disease. These studies are designed to test new treatment approaches and understand whether they can better reduce major heart-related events and improve patient outcomes.
- Heart failure with preserved or mildly reduced ejection fraction and obesity
- Cardiovascular disease and prevention of major cardiac events
- Type 2 diabetes, high blood pressure, and established cardiovascular disease
The site is contributing to trials that evaluate whether emerging therapies can improve protection against hospitalization, urgent care visits, and cardiovascular death.
Immune System Diseases
Clinical research in immune system diseases at this private practice site includes studies of ulcerative colitis and Crohn's disease. The main goal is to assess whether new therapies can help control inflammation, support symptom relief, and maintain disease improvement over time.
- Ulcerative colitis treatment and maintenance
- Crohn's disease treatment and maintenance
- Immune-mediated disease management
These trials reflect a strong interest in both short-term disease control and longer-term maintenance strategies for people living with chronic inflammatory conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Imed19 Betriebs GmbH
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Duvakitug as Maintenance Therapy in Participants with Moderately to Severely Active Ulcerative Colitis: A Phase 3, Randomized, Placebo-Controlled Study | Sanofi-Aventis Recherche & Developpement | Phase III | Recruiting | Jun 2026 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Duvakitug | 4 | Unknown | 2026-03-02 | 2026-07-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.